Want to see IN:SASTASUNDR full AI Analyst Report?
SASTASUNDR Stock Chart & Stats
₹304.15
₹0.00(0.00%)
At close: 4:00 PM EDT
₹304.15
₹0.00(0.00%)
Day’s Range― - ―
52-Week Range₹252.50 - ₹375.00
Previous CloseN/A
Volume63.42K
Average Volume (3M)650.00
Market Cap
₹8.68B
Enterprise Value₹9.51B
Total Cash (Recent Filing)₹302.16M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.66%
Share Statistics
EPS (TTM)-6.34
Shares Outstanding31,810,500
10 Day Avg. Volume380
30 Day Avg. Volume650
Financial Highlights & Ratios
PEG Ratio-6.86
Price to Book (P/B)1.27
Price to Sales (P/S)0.62
P/FCF Ratio-10.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-17.6
Revenue Forecast (FY)₹33.40B
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And GrowthThe strong 2026 revenue rebound indicates that demand has remained resilient despite the prior-year decline. If sustained, renewed top-line expansion can improve operating leverage, support broader customer reach, and provide a foundation for rebuilding profitability over the next several quarters.
Low Financial LeverageLow leverage gives the company greater financial flexibility while it works to improve earnings and cash generation. Modest debt reduces balance-sheet pressure, limits interest-related strain, and leaves more capacity to fund operations or strategic initiatives without relying heavily on additional borrowing.
Strong Equity CushionA sizable equity base provides a structural buffer against operating volatility and potential periods of weak performance. This cushion can improve resilience during the company’s profitability transition, support creditor confidence, and reduce the risk that losses immediately create balance-sheet stress.
Bears Say
Persistent Operating LossesPersistent operating losses show that the core business has not yet demonstrated dependable economic profitability. Without a sustained improvement in operating earnings, revenue growth may not translate into durable shareholder returns and the company may remain exposed to continued financial pressure.
Unsustainable Cash GenerationRepeatedly negative operating and free cash flow indicate that the business has generally not funded itself through internally generated cash. This weakens financial flexibility, increases reliance on working-capital movements or external funding, and limits the resources available for durable expansion.
Margin And Return DeteriorationSharp gross-margin compression threatens the economics of the recent revenue rebound, while weak and inconsistent return on equity shows poor conversion of capital into profits. Together, these trends suggest that growth quality remains fragile and that operational improvement is still unproven.
Sastasundar Ventures Limited News
SASTASUNDR FAQ
What was Sastasundar Ventures Limited’s price range in the past 12 months?
Sastasundar Ventures Limited lowest stock price was ₹252.50 and its highest was ₹375.00 in the past 12 months.
What is Sastasundar Ventures Limited’s market cap?
Sastasundar Ventures Limited’s market cap is ₹8.68B.
When is Sastasundar Ventures Limited’s upcoming earnings report date?
Sastasundar Ventures Limited’s upcoming earnings report date is Nov 12, 2026 which is in 12 days.
How were Sastasundar Ventures Limited’s earnings last quarter?
Sastasundar Ventures Limited released its earnings results on Aug 07, 2026. The company reported ₹0.799 earnings per share for the quarter.
Is Sastasundar Ventures Limited overvalued?
According to Wall Street analysts Sastasundar Ventures Limited’s price is currently Overvalued.
Does Sastasundar Ventures Limited pay dividends?
Sastasundar Ventures Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 3.66%. See more information on Sastasundar Ventures Limited dividends here
What is Sastasundar Ventures Limited’s EPS estimate?
Sastasundar Ventures Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sastasundar Ventures Limited have?
Sastasundar Ventures Limited has 31,810,500 shares outstanding.
What happened to Sastasundar Ventures Limited’s price movement after its last earnings report?
Sastasundar Ventures Limited reported an EPS of ₹0.799 in its last earnings report. Following the earnings report the stock price went up 0.957%.
Which hedge fund is a major shareholder of Sastasundar Ventures Limited?
Currently, no hedge funds are holding shares in IN:SASTASUNDR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sastasundar Ventures Limited
Established in 1989 and headquartered in Kolkata, India, Sastasundar Ventures Limited manages a comprehensive digital healthcare ecosystem across the country. In addition to its core healthcare activities, the company provides a variety of financial services, including loan financing, investments in shares and other securities, financial advisory, wealth management, and distribution. It also runs online portals such as sastasundar.com and retailershakti.com for the promotion of healthcare products and pathology services. Furthermore, Sastasundar offers crucial diagnostic services, encompassing both pathological and radiological investigations. Its business also extends to distributing pharmaceuticals and wellness items, delivering personalized health supplements, offering diet counseling, and providing health information. The company adopted its current name, Sastasundar Ventures Limited, in November 2016, having previously operated as Microsec Financial Services Limited.
Technical Analysis
Kopran Limited
―
Lincoln Pharmaceuticals Ltd
―
MedPlus Health Services Ltd.
―
Sanofi India Limited
―
Themis Medicare Limited
―